Cancer

Cell culture and mouse studies suggest CAR T cells targeting GD2 could help treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3A K27M mutation. In co-culture with patient-derived H3.3A K27M-mutant DIPG cells, anti-GD2 CAR T cells decreased cancer cell growth compared with CAR T cells targeting a control antigen. In five patient-derived xenograft (PDX) mouse models of H3.3A K27M-mutant diffuse midline glioma, the anti-GD2 CAR T cells decreased tumor growth. In one of the models, the anti-GD2 CAR T cells increased survival. Next steps include testing the anti-GD2 CAR T cells in DIPG patients.

Cancer Research UK and Autolus Ltd. have AUTO6 (1RG-CART), anti-GD2 CAR transduced T cells, in Phase I testing for neuroblastoma...